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Abstract
Background and Objective Technosphere® Insulin (TI), a human insulin powder for inhalation ( Afrezza®; MannKind Corporation, Westlake Village, CA, USA), is an ultra-rapid-acting inhaled insulin indicated to improve postprandial glycemic
control in patients with type 1 or type 2 diabetes mellitus (T1DM or T2DM). Because TI is absorbed across the alveolar
membrane, the objective of this analysis was to characterize its pulmonary safety.
Methods Pooled data from 13 phase 2/3 clinical studies in 5505 patients with T1DM or T2DM treated with TI, Technosphere
inhalation powder without insulin (TP; placebo), or active-comparator treatment were analyzed for incidences of respiratory
treatment-emergent adverse events (TEAEs), changes in pulmonary function, and lung malignancies. Radiographic changes
in the lungs were monitored in a subset of 229 patients.
Results Among 3017 patients receiving TI, the median duration of TI exposure was 168 days; median active-comparator and
TP exposure durations were 363 and 149 days for 2198 and 290 patients, respectively. Respiratory TEAEs were comparable
across treatments, except for a higher incidence of mild cough with TI in active-comparator studies (28.0% vs. 5.2%). Slight
reversible declines in pulmonary function from baseline were observed for TI versus TP and active-comparator treatments,
including in a subpopulation of patients with retrospectively identified lung dysfunction. Lung malignancies were reported
in two patients on active TI therapy with a smoking history. No clinically significant changes from baseline were observed
in radiographic images.
Conclusions Pulmonary safety assessment of the TI inhalation system did not identify any safety issues in individuals with
either T1DM or T2DM.
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Pulmonary safety of Technosphere Insulin, an ultrarapid-acting prandial insulin that is inhaled through the
mouth and absorbed via the alveoli, is of clinical interest,
and detailed safety information is reviewed here.
In this pulmonary safety analysis, data are assessed from
13 pooled phase 2/3 clinical trials with Technosphere
Insulin and demonstrate that respiratory treatment-emergent adverse events, changes in pulmonary function from
baseline, and rates of lung malignancies with inhaled
Technosphere Insulin, active-comparator, and placebo
treatment groups are similar. These data support that
inhaled Technosphere Insulin is not associated with an
excess of pulmonary safety events in the short term when
compared with usual insulin therapy.
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1 Introduction
Insulin therapy is an important component of standard care
of patients with diabetes mellitus (DM) and may be administered as a combination of basal (long-acting) insulin and
prandial (mealtime, short-acting) insulin [1]. Prandial insulin, traditionally self-administered via subcutaneous injection or infusion from an insulin pump, can also be delivered
via pulmonary inhalation. The first inhaled insulin to be
approved by the US Food and Drug Administration (FDA)
was EXUBERA® (insulin human [rDNA origin] inhalation
powder; Pfizer Inc, New York, NY, USA) in 2006, although
its use raised concerns about its possible effects on lung
function and theoretical risk of lung malignancies [2–4].
EXUBERA was ultimately withdrawn from the market by
the manufacturer [2].
In 2014, Technosphere® Insulin (TI; A
 frezza®; MannKind Corporation, Westlake Village, CA, USA) was
approved for the treatment of both type 1 DM (T1DM) and
type 2 DM (T2DM) [5]. Technosphere Insulin, a dry powder formulation of recombinant human insulin adsorbed
onto Technosphere microparticles for oral inhalation, is an
ultra-rapid-acting prandial inhaled insulin that has a faster
onset (approximately 12 min) and shorter duration (approximately 3 h) of action than currently available subcutaneously
injected insulins [5, 6].
Given the pulmonary administration route, it is clinically
important to assess and understand effects of TI on pulmonary safety/function. Technosphere Insulin has been investigated in numerous clinical studies in patients with T1DM
or T2DM, affording the opportunity to assess its pulmonary
safety profile in this combined cohort and in subpopulations
of those patients with underlying abnormalities in lung function. The current study presents an integrated analysis of
incidences of respiratory treatment-emergent adverse events
(TEAEs) and lung malignancies, changes in measures of
pulmonary function, and radiographic changes from baseline
using serial high-resolution computed tomographic (CT) or
magnetic resonance imaging (MRI) scans of patients over a
treatment period of up to 4 years.
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population were separated by placebo-controlled and activecomparator trials to allow for direct comparison between
TI and placebo or TI and active comparators. Additionally,
data were pooled and summarized for two inhaler types
(MedTone® and G
 en2®; MannKind Corporation, Westlake
Village, CA, USA), and comparative data demonstrated that
overall pulmonary safety profiles were similar between TI
Gen2- and TI MedTone-treated groups. For pooled studies,
the analysis population was the safety population, which
was defined as all randomized patients who received one
or more doses of study medication. Although there were
variations in study designs between trials, patients generally
were excluded if they had renal dysfunction, renal disease, or
serum creatinine levels between 1.5 and 2.0 mg/dL for males
or 1.3 and 1.8 mg/dL for females. Patients with a history
of chronic obstructive pulmonary disease (COPD), asthma,
or other clinically important pulmonary diseases were also
excluded from the studies. Although the inclusion/exclusion
criteria were designed to exclude patients diagnosed with
asthma or COPD, subpopulations of patients with mild subclinical lung dysfunction from the pooled phase 2/3 studies
were retrospectively identified to assess the safety of TI in
patients with underlying lung disease.
For studies evaluating pulmonary function, data were
presented as individual studies because of differing study
designs and treatment durations. These studies included
MKC-TI-171 (open-label study in T1DM with 24-week
treatment period), MKC-TI-162 and substudy MKC-TI-164
(open-label studies in T2DM with 16-week treatment periods), and MKC-TI-175 (placebo-controlled, double-blind
study in T2DM with 24-week treatment period).
High-resolution CT or MRI scans of the lungs were performed to monitor the development of lung abnormalities in
a population of 229 patients with T2DM from MKC-TI-010,
a 4-year, open-label extension study designed to evaluate
safety and tolerability of TI.
All studies were approved by appropriate independent
ethics committees or institutional review boards and monitored by independent data-safety-monitoring boards. All
patients provided written informed consent.

2.2 Treatments and Exposure

2 Methods
2.1 Studies and Study Populations
Data from all 13 controlled phase 2/3 clinical studies of TI
for treatment of T1DM or T2DM with a planned continuous
study-treatment exposure of > 14 days that were completed
by 31 July 2013 were pooled for analysis (see Electronic
Supplementary Material). Data from the pooled safety

Treatments included TI, Technosphere inhalation powder
without insulin (TP; placebo), or active-comparator treatment, which included subcutaneous insulin (e.g., insulin
aspart, insulin lispro), oral glucose-lowering drugs, or usual
care.

2.3 Pulmonary Safety
Primary pulmonary safety endpoints were respiratory
TEAEs, including cough. A TEAE was defined as an AE
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(except for hypoglycemia) that worsened in severity on or
after study day 1 and within 30 days of the last treatment
dose. Respiratory TEAEs in the pooled studies, including
cough, were summarized by preferred term and coded using
the Medical Dictionary for Regulatory Activities (MedDRA)
version 15.1.
Cough is an anticipated side effect of dry powder inhalation and therefore was also prespecified as an expected
event of special interest. Cough events as TEAEs of special
interest were monitored and reported on a separate cough
case-report form (CRF). Information collected included
cough frequency (single defined, intermittent, continuous),
relationship to treatment, and absence or presence of sputum production. In cases of mild cough, the event may not
have been recorded as an AE. Events collected on cough
CRFs were excluded from respiratory TEAEs summarized
by preferred term.
To evaluate changes from baseline in pulmonary function for the individual studies (MKC-TI-171, MKCTI-162/164, and MKC-TI-175; Electronic Supplementary
Material), formal spirometry testing was employed as previously described by Miller et al. [7]. Pulmonary endpoints
included forced expiratory volume in 1 second (FEV1) and
forced vital capacity (FVC). All studies strictly adhered to
American Thoracic Society or European Respiratory Society
guidelines [7].
High-resolution CT or MRI lung scans were performed
in 229 patients with T2DM (study MKC-TI-010). Of these
patients, 206 had a baseline image and ≥ 1 subsequent
image taken, allowing for assessment and inclusion in the
analysis population. Images of the lungs were taken at
baseline (visit 1) and annually thereafter over the 4-year
treatment period. Scans were reviewed for abnormalities
by an independent radiologist who was blinded to patient
identity, investigator site, examination dates, sequence of
examinations, and reason for imaging. Qualitative assessment criteria included interlobular septal thickening,
ground-glass opacities, tree-in-bud opacities, parenchymal
abnormalities, consolidation, nodules or masses, bronchial
abnormalities, pleural abnormalities, and pleural effusions.
Patients found to be absent of all criteria for both lungs
were deemed normal. Any result other than normal was
submitted for additional review with clinical data to an
independent board-certified radiologist and an independent
board-certified pulmonologist. Secondary interpretations,
based on the images and clinical data, included whether
the patients’ images were normal; abnormal, not clinically significant; or abnormal, clinically significant. Study
investigators reviewed high-resolution CT or MRI reports
and assessed the clinical significance of abnormalities.
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2.4 Statistical Analysis
For TEAE reports, event rates were calculated by dividing
number of events by patient exposure time. For pulmonary
function tests, a mixed-effect model repeat-measurement
analysis was performed to assess mean changes in F
 EV1
and FVC from baseline values. For change from baseline
calculations, baseline values were defined as the last measurements collected on or before study day 1 (date the first
dose of study medication was administered).

3 Results
3.1 Patient Disposition and Baseline Characteristics
A total of 5505 patients were included in the overall safety
population. Of these, 3017 received TI (413 in placebocontrolled studies and 2604 in active-comparator studies),
290 received TP and 2198 received active-comparator
treatment. Patients in the three treatment cohorts had similar demographic characteristics, duration of diabetes, and
smoking histories (Table 1).
Among 3017 patients receiving TI, 2023 (67.1%) completed treatment. More patients discontinued prematurely
in the TI (32.9%) versus TP (20.0%) and active-comparator (22.0%) cohorts, with the most common reasons for
discontinuation being patient withdrawal of consent for
personal reasons, lack of efficacy, and dissatisfaction with
therapy.

3.2 Exposure to Treatment
Median (range) duration of exposure to treatment was
168 (1–764), 149 (2–205), and 363 (0–810) days for
patients receiving TI, TP, and active-comparator treatment, respectively. The 3017 patients receiving TI
had varying treatment exposure times (TI exposure:
0–3 months, n = 896; > 3–6 months, n = 978; > 6–12 months,
n = 419; > 12 months, n = 724).

3.3 Respiratory Treatment‑Emergent Adverse
Events
The overall incidence of respiratory TEAEs occurring
in ≥ 2% of each cohort was higher for TI (45.2%) than
for TP (35.9%) and active-comparator (31.0%) treatments. The most common respiratory TEAE summarized
by MedDRA preferred term was cough. Cough incidence
was similar between patients receiving TI (20.3%) and TP
(19.7%) in placebo-controlled studies and higher for patients
receiving TI (28.0%) versus active comparator (5.2%) in
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Table 1  Baseline characteristics of the safety population from pooled studies of Technosphere Insulin
Parameter

Sex, n (%)
Male
Female
Race, n (%)
White
Black
Hispanic
Asian
Other
Age group, years, n (%)
18–64
65–74
≥ 75
BMI, mean (SD), kg/m2
Duration of diabetes, mean (SD), y
Past smoker, n (%)
Cigarettes per day, mean (SD)
Number of years smoked, mean (SD)

Placebo-controlled studies

Active-comparator studies

TI (n = 413)

TP (n = 290)

TI (n = 2604)

Active comparator (n = 2198)

222 (53.8)
191 (46.2)

139 (47.9)
151 (52.1)

1310 (50.3)
1294 (49.7)

1123 (51.1)
1075 (48.9)

327 (79.2)
26 (6.3)
55 (13.3)
2 (0.5)
3 (0.7)

207 (71.4)
18 (6.2)
55 (19.0)
7 (2.4)
3 (1.0)

2164 (83.1)
123 (4.7)
238 (9.1)
51 (2.0)
28 (1.1)

1844 (83.9)
88 (4.0)
193 (8.8)
41 (1.9)
32 (1.5)

332 (80.4)
75 (18.2)
6 (1.5)
30.8 (4.7)
9.2 (5.4)
135 (32.7)
17.6 (16.4)
19.4 (11.9)

233 (80.3)
52 (17.9)
5 (1.7)
31.8 (4.6)
8.8 (5.0)
84 (29.0)
18.1 (15.7)
19.3 (12.1)

2304 (88.5)
286 (11.0)
14 (0.5)
29.2 (5.2)
13.2 (9.1)
680 (26.1)
15.5 (13.6)
16.5 (11.9)

1965 (89.4)
216 (9.8)
17 (0.8)
29.1 (5.2)
13.5 (9.0)
590 (26.8)
16.7 (14.3)
16.6 (11.7)

BMI body mass index, SD standard deviation, TI Technosphere Insulin, TP Technosphere inhalation powder without insulin (placebo)

active-comparator studies (Table 2). When recorded as a
TEAE of special interest on a separate CRF, the incidence of
patient-reported cough was also similar between TI (21.5%)
and TP (20.3%) in placebo-controlled studies and higher for
TI (27.0%) vs active comparator (5.1%) in active-comparator
studies (Table 3).
Cough was most commonly described as mild, intermittent, and limited to a single defined event that occurred
within 10 min after TI inhalation. Cough was not persistent,
as incidence was highest within the first week of TI treatment and declined over the following 4–8 weeks. Cough
was generally nonproductive and not associated with chronic
sputum production. Treatment discontinuation due to cough
was uncommon, occurring in a small proportion (2.8%) of
patients receiving TI. Other respiratory TEAEs of special
interest, such as asthma, wheezing, bronchospasm, and
bronchial reactivity, were uncommon (incidence, < 0.5%)
for patients receiving TI.
Upper respiratory tract infection (URTI) and nasopharyngitis were the next most common respiratory TEAEs summarized by preferred term (Table 2). Incidences of URTIs
were comparable between cohorts in placebo-controlled (TI
4.6%; TP 4.8%) and active-comparator (TI 10.2%; active
comparator 10.9%) studies. Similarly, incidences of nasopharyngitis were comparable across cohorts in placebocontrolled (TI 7.7%; TP 8.3%) and active-comparator (TI
7.2%; active comparator 7.8%) studies.

In the pooled, controlled phase 2/3 studies, there were
no deaths due to a primary respiratory TEAE. Respiratory
TEAEs were noted as the cause of early discontinuation in
4.6% of patients treated with TI, compared with 0.1% of
patients in the active-comparator cohorts, respectively. This
difference was predominantly driven by cough (TI 2.8%;
active comparator 0%), followed by dyspnea (TI 0.5%; active
comparator 0%).

3.4 Pulmonary Function
In study MKC-TI-171, there was a reduction in FEV1 from
baseline to week 24 in patients with T1DM. A greater overall reduction was seen in patients receiving TI (Gen2 inhaler
− 0.07 L; MedTone inhaler − 0.08 L) than in patients receiving insulin aspart (− 0.03 L; Fig. 1a), with absolute differences in FEV1 between TI and active-comparator treatment
of − 0.04 L (Gen2 inhaler) and − 0.05 L (MedTone inhaler).
Differences were no longer present at the 28-week follow-up
visit (i.e., 4 weeks after TI treatment completion). Additionally, there was a small decline in mean change from baseline in FVC for patients receiving either TI or insulin aspart
over the 24-week treatment period, with less of a decline in
the insulin aspart cohort (Fig. 1b). These changes were not
observed at week 28 of treatment.
In study MKC-TI-175, patients with T2DM receiving TI
experienced greater declines in FEV1 from baseline to week

Pulmonary Safety Assessment of Technosphere® Insulin
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Table 2  Respiratory TEAEs by preferred term observed in pooled studies of Technosphere Insulin
TEAEs, n (%)

Cough
Upper respiratory tract infection
Nasopharyngitis
Bronchitis
Oropharyngeal pain
Throat irritation
Productive cough
Sinusitis
Dyspnea
Viral respiratory infection

Placebo-controlled studies

Active-comparator studies

TI (n = 413)

TP (n = 290)

TI (n = 2604)

Active comparator (n = 2198)

84 (20.3)
19 (4.6)
32 (7.7)
12 (2.9)
12 (2.9)
5 (1.2)
11 (2.7)
4 (1.0)
1 (0.2)
2 (0.5)

57 (19.7)
14 (4.8)
24 (8.3)
10 (3.4)
8 (2.8)
4 (1.4)
3 (1.0)
3 (1.0)
2 (0.7)
5 (1.7)

729 (28.0)
265 (10.2)
188 (7.2)
78 (3.0)
65 (2.5)
63 (2.4)
99 (3.8)
51 (2.0)
40 (1.5)
7 (0.3)

114 (5.2)
239 (10.9)
172 (7.8)
58 (2.6)
25 (1.1)
3 (0.1)
18 (0.8)
49 (2.2)
6 (0.3)
5 (0.2)

Adverse events were coded using the MedDRA (version 15.1)
MedDRA Medical Dictionary for Regulatory Activities, TEAE treatment-emergent adverse event, TI Technosphere Insulin, TP Technosphere
inhalation powder without insulin (placebo)

Table 3  Incidence and characteristics of cough as a TEAE of special interest in pooled studies of Technosphere Insulin
Placebo-controlled studies
TI (n = 413)

Incidence of cough
89 (21.5)
Patient-reported cough, n (%)a
Total cough episodes, n
207
Characteristics of cough episodes, n (percentage of cough episodes)b
Frequency of cough
Continuous
14 (6.8)
Intermittent
101(48.8)
Single defined
92 (44.4)
Cough occurred within 10 min of drug inhalation
Yes
156 (75.4)
No
51 (24.6)
Cough produced sputum
Yes
29 (14.0)
No
120 (58.0)
Inciting event
Spirometry
5 (2.4)
Study drug
113 (54.6)
Other
37 (17.9)

Active-comparator studies
TP (n = 290)

TI (n = 2604)

Active
comparator
(n = 2198)

59 (20.3)
168

703 (27.0)
1257

112 (5.1)
131

11 (6.5)
123 (73.2)
34 (20.2)

77 (6.1)
736 (58.6)
444 (35.3)

10 (7.6)
99 (75.6)
21 (16.0)

139 (82.7)
29 (17.3)

969 (77.1)
285 (22.7)

16 (12.2)
83 (63.4)

11 (6.5)
56 (33.3)

175 (13.9)
606 (48.2)

26 (19.8)
79 (60.3)

3 (1.8)
107 (63.7)
10 (6.0)

1 (0.1)
445 (35.4)
119 (9.5)

0
0
40 (30.5)

Only data from cough case-report forms are presented in this table. Cough events reported as adverse events are excluded
TEAE treatment-emergent adverse event, TI Technosphere Insulin, TP Technosphere inhalation powder without insulin (placebo)

a

b

Percentages are based on the number of patients in each treatment cohort from the safety population

Percentages are based on the total number of cough episodes in each treatment cohort. The ‘No’ category might include events that happened
while patient was temporarily not on treatment
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12 (− 0.08 L) and week 24 (− 0.13 L) than patients receiving TP (− 0.04 L at week 12 and week 24; Fig. 1c), with
a treatment difference at week 24 of − 0.09 L (95% confidence interval [CI], − 0.12, − 0.05). There were also small
declines in mean FVC from baseline to week 12 and week
24 for both TI and TP cohorts. The FVC declines in the TI
cohort (week 12, − 0.07 L; week 24, − 0.12 L) were greater
than those of the TP cohort (week 12, − 0.04 L; week 24,
− 0.03 L; Fig. 1d), with a treatment difference at week 24
of − 0.09 L (95% CI, − 0.13, − 0.04). At week 28, 4 weeks
after stopping treatment, mean F
 EV1 and FVC values for
patients receiving TI returned to levels similar to those of
patients receiving TP.
Overall, a high percentage of patients across all treatment cohorts in the MKC-TI-171 and MKC-TI-175 studies had a small (0–5%) decline from baseline to the last

0.5
0.4
0.3

TI Gen2 inhaler (3.34 L)
TI MedTone inhaler (3.37 L)
Insulin aspart (3.27 L)

0.2
0.1
0
-0.1
-0.2
-0.3
-0.4
-0.5
Baseline

c

0.5

12
Week

24

d
TI (2.8 L)
TP (2.8 L)

0.2
0.1
0
-0.1
-0.2
-0.3

0.4
0.3
0.1
0
-0.1
-0.2
-0.3
-0.4

0.5

28

MKC-TI-175
TI (3.5 L)
TP (3.4 L)

0.1
0
-0.1
-0.2
-0.3
-0.4

Fig. 1  In study MKC-TI-171 of patients with T1DM in which TI was
administered with either the MedTone or Gen2 inhaler, changes from
baseline in a FEV1 and b FVC. In study MKC-TI-175 of patients with
T2DM (safety population), changes from baseline in c FEV1 and d
FVC. Median baseline values are included in graph legends. FEV1

24

0.2

-0.5
Baseline

28

12
Week

0.3

-0.4
24

TI Gen2 inhaler (3.99 L)
TI MedTone inhaler (4.18 L)
Insulin aspart (3.99 L)

0.2

-0.5
Baseline

12
Week

MKC-TI-171

0.4
Mean (SE) change
from baseline in FVC, L

0.3

0.5

-0.5
Baseline

28

MKC-TI-175

0.4
Mean (SE) change
from baseline in FEV1, L

b

MKC-TI-171

Observed mean (SE) change
from baseline in FVC, L

Observed mean (SE) change
from baseline in FEV1, L

a

study measurement in FEV1 (Fig. 2a, b) and FVC (data not
shown). In both studies, a majority of TI-treated patients
had observed declines in pulmonary function at time of last
measurement. This distribution was similar at week 12 and
week 24 of treatment.
Consistent with results observed in MKC-TI-171 and
MKC-TI-175, differences in FEV1 and FVC changes from
baseline between patients with T2DM receiving either TI
plus insulin glargine or insulin aspart plus insulin glargine in
study MKC-TI-162 were small (differences in mean changes
from baseline [TI cohort minus active-comparator cohort]:
FEV1 at week 6, − 0.07 L; FEV1 at week 16, − 0.07 L; FVC
at week 6, − 0.07 L; FVC at week 16, − 0.06).

12
Week

24

28

forced expiratory volume in 1 second, FVC forced vital capacity, SE
standard error, T1DM type 1 diabetes mellitus, T2DM type 2 diabetes
mellitus, TI Technosphere Insulin, TP Technosphere inhalation powder without insulin (placebo)
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3.5 Pulmonary Safety in Special Populations
Among the pooled safety population, 101 patients were retrospectively identified with subclinical reversible airway
dysfunction, defined as patients with a > 12% and > 0.2 L
improvement in FEV1 pre- to post-bronchodilator at the
screening visit (TI, n = 50; TP, n = 2; active comparator,
n = 49). Among these patients, cough was the most common respiratory TEAE and was reported in 30.0% of
patients in the TI cohort, compared with 12.2% in the TP/
active-comparator cohort. In lung function analyses, mean
changes in F
 EV1 values from baseline over 24 months
slightly decreased over time (− 0.05 L) for the TI cohort
and increased over time for the TP/active-comparator cohort
(0.10 L). Similarly, the TI cohort demonstrated a greater
decline from baseline in FVC over 24 months (− 0.16 L),
whereas the TI/active-comparator cohort demonstrated an
improvement from baseline (0.09 L).
Among the pooled safety population, 61 patients (TI,
n = 38; TP, n = 2; active comparator, n = 21) were retrospectively identified as having subclinical fixed obstructive lung dysfunction, defined as patients aged > 40 years
with a history of smoking and a post-bronchodilator
a

Patients, %

46.9

During the clinical trial program, there were two reported
lung malignancies in 3283 patients (2747 patient-years
of follow-up) receiving TI treatment and no cases of lung
malignancy in 2205 patients (2169 patient-years of follow-up) receiving active-comparator treatment. One case
was a neuroendocrine tumor involving the lung, which
was diagnosed 71 days after the last TI dose; the second
case was a non–small-cell bronchogenic carcinoma, which

54.5
49.7

TI Gen2 inhaler
TI MedTone inhaler

40
30

26.2
20.7 19.4

20

0

0.6

≤-20

0.7 0.6 0.6

23.9

2.8 3.2

1.4 2.6 1.3

5.1

1.4

>-20 to -15 >-15 to -10 >-10 to -5
>-5 to 0
>0 to 5
>5 to 10
>10 to 15 >15 to 20
FEV1 change from baseline to last measurement, %

>20

MKC-TI-175

50
40

35.2

30

23.3

20

39.5

TI
TP
26.5
20.8

19.7

10.7

10
0

Insulin aspart

30.1

8.3

10

Patients, %

3.6 Lung Malignancies

MKC-TI-171

60
50

b

FEV1/FVC ratio of < 70%. Cough was observed in 21.5%
of these patients receiving TI, compared with 0% of
patients receiving TP or active-comparator treatment. Over
24 months, mean changes in F
 EV1 from baseline slightly
decreased for patients receiving TI (− 0.11 L) and slightly
increased for patients receiving TP or active-comparator
treatment (0.09 L). At 24 months, the TI cohort also demonstrated a decline from baseline in mean FVC (− 0.16 L),
whereas the TP/active-comparator cohort demonstrated
an improvement (0.13 L). In both retrospectively defined
subpopulations, no bronchospasm AEs were reported.

1.3 0.7

≤-20

4.4
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Fig. 2  Distribution of percentage change from baseline to last measurement in FEV1 in a study MKC-TI-171 (patients with T1DM in
which TI was administered with either the MedTone or Gen2 inhaler)
and b study MKC-TI-175 (patients with T2DM). FEV1 forced expira-

tory volume in 1 second, T1DM type 1 diabetes mellitus, T2DM type
2 diabetes mellitus, TI Technosphere Insulin, TP Technosphere inhalation powder without insulin (placebo)

980

was diagnosed 2 months after TI discontinuation. In both
cases, the patients had a history of cigarette exposure of
approximately 40 pack-years. Additionally, two cases of
non–small-cell lung cancer in nonsmoking patients were
diagnosed after completion of participation in clinical trials (more than 2 years after completion of TI treatment).
One of these tumors was later reclassified as a pulmonary
blastoma. Longer-term follow-up of individuals receiving
usual care was not routinely available.

3.7 High‑Resolution CT and MRI
A total of 206 (N = 229) patients in the analysis population of study MKC-TI-010 received TI and had a baseline
image plus one or more subsequent high-resolution CT
or MRI image taken. At the 12-month follow-up, of 184
patients with baseline and follow-up images taken, 70.7%
had normal radiologic images; 28.3% had abnormal, not
clinically significant images; and 1.1% had abnormal,
clinically significant images. Of 137 patients with images
considered normal at baseline, 136 had normal or abnormal, not clinically significant images at the 12-month follow-up; of the four patients with abnormal, clinically significant radiologic images at baseline, one had abnormal,
clinically significant images and three had abnormal, not
clinically significant images at the 12-month follow-up.
Over the study course, six (2.6%) patients had local
readings of lung nodules on high-resolution CTs. Although
causality ultimately cannot be defined on the basis of these
radiologic reviews, five were judged by the investigator to
be unlikely related to TI exposure.

4 Discussion
Inhaled insulin offers numerous potential advantages over
subcutaneously injected insulin, including faster insulin
absorption rates, more rapid onset and offset of action,
improved postprandial glucose control, and a lower risk of
latent hypoglycemia [8]. Given the novel delivery system
of inhaled insulin, pulmonary safety is of particular clinical interest, and the incidence of AEs and drug effects on
the respiratory system are important to understand.
The most common respiratory AEs associated with
inhaled medications such as inhaled corticosteroids
for asthma or inhaled antibiotics for airway infections
include bronchoconstriction, dysphonia, throat irritation,
and cough [9, 10]. In the current pooled safety analysis,
the most common respiratory TEAE associated with TI
was cough. Cough was generally mild and nonproductive, occurred within 10 min of inhalation, was observed
early in the first week of treatment, and diminished over
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time, consistent with previously published studies of TI
[11–13]. Incidence of cough was similar between TI and
TP in placebo-controlled trials but higher for TI in activecomparator trials, suggesting that the TI excipient is associated with cough. As expected, cough was noted as the
cause of early discontinuation in more patients receiving
TI than in patients receiving active-comparator treatments,
although this occurred in a minority of patients (2.8%)
and discontinuation may have been affected by the openlabel design of the controlled studies. Patients who experienced a respiratory TEAE may have been more likely
to discontinue treatment than if they were receiving comparator subcutaneous insulin in this open-label design,
as TI is inhaled. The current analysis does not allow for
assessment of potential bias. Incidences of other respiratory TEAEs, including asthma, wheezing, bronchospasm,
and bronchial reactivity, were low, occurring in < 0.5% of
patients receiving TI.
Potential concerns with inhaled medications include
lung toxicity, inflammation, and anatomical injury resulting from the active drug product or the powder constituents. In the high-resolution CT/MRI analysis (MKCTI-010), a small proportion (n = 2 [1.1%]) of patients had
radiologic findings that were considered “abnormal, clinically significant” at the time of their 12-month CT/MRI
measurement, and one of these patients had “abnormal,
clinically significant” CT/MRI scans before treatment
began. Overall, the observed radiologic findings are not
suggestive of a safety signal in patients treated with TI for
at least 12 months. Published results from high-resolution
CT/MRI analyses with the inhaled insulin EXUBERA also
showed no significant changes in scans from baseline, further indicating that insulin delivery via pulmonary inhalation does not appear to substantially alter lung anatomy
[3]. These findings support the conclusion that decreased
pulmonary function is not related to drug-induced lung
abnormalities or inflammation but may be attributable to
other factors associated with deep-lung inhalation systems.
Diabetes is associated with a progressive decline in pulmonary function that exceeds the decline observed in populations without diabetes [14]. This decline may be due to
several factors, including overall higher body mass index
(BMI) and chronic hyperglycemia effects, as indicated by
higher hemoglobin A1C levels [14, 15]. The main factor
accounting for the relationship between glycemic control
and lung function may be the metabolic pathways related
to hyperglycemia; however, several other mechanisms have
been proposed that also consider BMI, including decreased
respiratory muscle strength, impaired lung elasticity, defects
in pulmonary surfactants, and low-grade chronic inflammation [16]. In the current study, pulmonary function was
evaluated in three individual studies: MKC-TI-171, MKCTI-175, and MKC-TI-162/164. These studies reported that
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there were greater (though small) declines in mean F
 EV1
and FVC from baseline for the TI versus TP and activecomparator cohorts. When looking at the distribution of
percentage change from baseline, the observed changes in
mean FEV1 and FVC for TI-treated patients were driven by
slight declines in pulmonary function (as demonstrated by
a slight shift to the left in distribution in Fig. 2) among a
high percentage of TI-treated patients and not by significant
declines among a low percentage of TI-treated patients (i.e.,
outliers). For all trials assessed in the current study, such
declines resolved 4 weeks after the end-of-treatment period,
regardless of exposure duration. Lung function decline also
occurs in healthy, aging individuals, with normal age-related
declines in pulmonary function reported as ranging from
0.02 to 0.05 L per year [17].
In the retrospectively defined subpopulation of patients
with mild, subclinical lung dysfunction, cough was the
most frequent respiratory TEAE, with an incidence similar
to that of the overall safety population without underlying
lung disease. These results support those from phase 1
studies in prospectively defined populations with asthma
and COPD in which cough was the most frequent respiratory TEAE [2, 18]. Although acute bronchospasm was
observed after TI administration in five of 17 asthmatic
patients in one of the aforementioned phase 1 studies, it
could be prevented by pretreatment with bronchodilators
[2]. Bronchospasm was not reported in phase 2/3 studies
in patients with either reversible airway disease or fixed
obstructive lung dysfunction. In the retrospective analyses
presented here, there was a greater decline in pulmonary
function in patients with underlying lung dysfunction
receiving TI compared with those receiving TP or activecomparator treatments. This is also consistent with phase 1
studies in prospectively defined asthma and COPD populations, in which a moderate decline in pulmonary function
was seen immediately (15–18 min) after TI inhalation [2,
18]. However, the retrospectively defined studies presented
here are limited by a small patient population evaluated at
the completion of the study (month 24); therefore, additional studies are necessary to better establish the efficacy
and safety of TI in these populations.
Chronic hyperinsulinemia has been proposed to play a
role in the growth of non-small-cell lung cancer, with data
suggesting that chronic stimulation of the insulin-like growth
factor-1 signaling pathway may promote the rapid growth of
existing neoplasms [19, 20]. This observation is supported
by data demonstrating an overall increased risk of any malignancy in the population of patients with long-standing diabetes. Comparisons between lung cancer incidences in the
referenced TI clinical studies and published incidences in
other studies or in the general diabetes population are limited by differences in demographics (age), study populations (smokers, ex-smokers, nonsmokers), and the low rate
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of population events. For example, comparative incidences
assessed from studies involving nonsmokers in the general
diabetes population most likely underestimated the expected
incidence of lung malignancies in the TI population because
ex-smokers were included in the TI studies. However, the
overall incidence of lung malignancies in the TI study population (0.8 cases per 1000 patient-years) was similar to that
of the general population of patients with diabetes, both for
smokers and for nonsmokers (incidence of 0.5–2.0 cases
per 1000 patient-years) [21, 22]. There were four cases of
lung malignancies reported among TI-treated patients: two
were reported during the program in patients who were exsmokers with a long history of cigarette exposure, and two
were reported ≥ 2 years after trial completion in nonsmokers.
Similarly, in a 2-year observational follow-up study (FUSE)
in patients previously treated with the inhaled insulin EXUBERA, it was reported that the increased risk of lung cancerrelated mortality in EXUBERA-treated patients including
nonsmokers and those with a history of smoking was low
(0.5 cases per 1000 patient-years) and was similar to the estimated lung cancer mortality rate in the general population of
patients with diabetes [4]. Additionally, most (7/8) patients
with lung cancer-related mortality (EXUBERA group, n = 5;
active-comparator group, n = 2) were prior smokers [4].
These data support the limited risk of malignancy observed
in patients using inhaled insulins as compared with the
general population of patients with diabetes. However, the
relatively low total exposure and short exposure duration in
the studies included in the current analysis support the need
for further long-term follow-up of patients to better inform
conclusions regarding the risk of malignancy in patients
receiving inhaled TI treatment.
The patients included in this pooled pulmonary safety
analysis were participants in randomized controlled trials
that were part of the TI phase 2/3 clinical program. Randomized controlled trials aim to reduce bias through strict
inclusion and exclusion criteria; however, these criteria
may exclude many patients typically seen in clinical care,
including patients with multiple co-morbidities, potentially
limiting the generalizability of the results [23]. Real-world
studies and longer-term pharmacovigilance will be needed
to further assess the long-term safety of TI in a more heterogenous patient population to broaden the applicability of
the results found here.
Another potential limitation of this analysis is the duration of TI exposure for each study, with a maximum time of
TI exposure of 764 days for the pooled analysis and 4 years
for MKC-TI-010. These relatively short exposure durations
limit the ability to draw conclusions regarding any longterm effects of TI treatment (beyond 4 years) on pulmonary
safety, particularly risk of malignancy; additional long-term
and follow-up studies will be helpful to further clarify the
risk profile.
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5 Conclusions
This analysis of long-term TI use in clinical studies provides
a pulmonary safety assessment of inhaled insulin using the
Technosphere powder inhalation platform. No significant or
persistent pulmonary safety concerns were identified across
the 13 clinical trials included in this analysis, providing further support for the use of TI treatment in adults with T1DM
or T2DM.
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